U.S. Semiconductors Stock News

Mixed quarter and higher guidance put Marriott Vacations Worldwide (VAC) in focus Marriott Vacations Worldwide (VAC) is back on investors’ radar after a mixed first quarter, where earnings missed estimates but revenue exceeded expectations, alongside updated guidance and operational changes. See our latest analysis for Marriott Vacations Worldwide. The stock’s recent momentum has been strong, with a 30-day share price return of 16.04% and a year to date share price return of 52.06%, even...

Why Central Garden & Pet is on investors’ radar today Central Garden & Pet (CENT) has been drawing attention after a period of steady share price gains, with the stock last closing at US$40.16 and posting positive returns over the past month and past 3 months. See our latest analysis for Central Garden & Pet. The recent 1 month share price return of 5.3% and 3 month return of 8.8% sit within a stronger year to date share price gain of 25.7%. The 3 year total shareholder return of 35%...

Booz Allen Hamilton Holding (BAH) has drawn investor attention after recent trading left the stock about 21% lower over the past year, despite a market value of roughly US$9.5b and annual revenue of US$11.2b. See our latest analysis for Booz Allen Hamilton Holding. Over the past year, Booz Allen Hamilton Holding’s share price has lacked positive momentum, with the stock down 21.11% on a total shareholder return basis. The 30 day share price return of 3.17% suggests a modest near term recovery...

Wondering if Alphabet stock still offers value after a strong run, or whether the current price already reflects the story you are buying into? At a last close of US$368.53, Alphabet is up 16.9% year to date and around 112.9% over the past year, even though the stock has fallen 3.1% in the last week and 8.1% over the past month. Recent news coverage has focused on Alphabet's ongoing role in online search and digital advertising, along with its push into artificial intelligence tools and...

Vera Therapeutics stock snapshot after recent performance Vera Therapeutics (VERA) has drawn fresh attention after recent price moves, with the stock closing at $32.29 and showing mixed returns, including a decline of about 11% over the past month. See our latest analysis for Vera Therapeutics. Recent weakness in the share price, including a decline of about 11% over the past month and a year to date share price return down 33.6%, contrasts with a 1 year total shareholder return of 42.3% and...

In early June 2026, Antero Resources was highlighted for its strong growth profile and leading U.S. natural gas liquids and LNG exposure amid geopolitical tensions that have tightened global energy markets, even as recent insider share sales created some concerns. Analysts and hedge funds have recently emphasized that Antero’s export-oriented NGL and LNG footprint could benefit from current Middle East supply disruptions, reinforcing its role as a key U.S. supplier in a reshaped global...

Insmed (INSM) is back in focus after reporting strong early physician conviction and broad prescribing intent for its newly launched drug brensocatib, along with fresh equity awards for more than 100 newly hired employees. See our latest analysis for Insmed. Despite strong interest in brensocatib and recent equity awards tied to new hiring, Insmed’s share price has come under pressure, with a 1-day share price return of down 10.20% and a year to date share price return of down 46.80%. At the...

Evercore Inc. recently outlined its ongoing capital return program, highlighting an 18th consecutive annual increase in its quarterly dividend and continued share repurchases, supported by earnings and disciplined balance sheet management. The acquisition of UK advisory firm Robey Warshaw is expected to broaden Evercore’s EMEA advisory platform by adding deep FTSE 100 and multinational boardroom relationships to its existing capabilities. We’ll now examine how the Robey Warshaw acquisition...

Opera’s Q1 Beat and Capital Return Plans Put Focus on AI and Cash Use Opera (OPRA) reported Q1 2026 revenue and adjusted EBITDA above the high end of its guidance, raised full year forecasts, and announced a US$300 million buyback alongside its recurring dividend. See our latest analysis for Opera. Despite the Q1 beat and new AI browser features, Opera’s share price has eased about 3% over the past month but is still up roughly 21% over 90 days and 28% year to date, while the five year total...

McDonald's (MCD) is drawing fresh attention after unveiling its McDonald's > NEXT growth plan and launching a FIFA World Cup 26 promotion, moves that come as lower income consumers face growing budget pressure. See our latest analysis for McDonald's. Despite the McDonald's > NEXT rollout and the high-profile FIFA World Cup 26 campaign, the stock has been under pressure. The share price is down about 15% over the past 90 days and the 1-year total shareholder return is also slightly negative,...

On May 27, 2026, Microvast Holdings, Inc. reported that Chief Accounting Officer Eric N. Garcia left the company, shortly before law firm Halper Sadeh LLC began investigating whether certain officers and directors breached fiduciary duties to shareholders. This combination of an accounting leadership change and a shareholder-focused legal review raises fresh questions about Microvast’s governance, oversight, and internal controls. Next, we’ll examine how the investigation into potential...

Dividend affirmation against a backdrop of heavy short interest Medical Properties Trust (MPT) affirmed its regular quarterly dividend at US$0.09 per share, even as the stock carries the highest reported short interest among REITs and continues to face questions about its balance sheet. See our latest analysis for Medical Properties Trust. At a share price of US$4.98, Medical Properties Trust has posted a 1 year total shareholder return of 17.71%, although its 5 year total shareholder return...

Exponent (EXPO) has been drawing attention after recent trading left the stock down about 3% over the past month and roughly 17% over the past 3 months, prompting investors to reassess its valuation. See our latest analysis for Exponent. At a share price of $59.66, Exponent’s recent momentum has been soft, with the 7 day share price return of 2.3% set against a 90 day share price decline of 17% and a 1 year total shareholder return that is down 21.56%. This points to fading enthusiasm and a...

In the recent past, Armstrong World Industries reported Q1 results showing solid revenue growth driven by stronger Mineral Fiber average unit values and higher volumes, alongside double-digit sales gains in Architectural Specialties, but it missed analysts’ adjusted operating income estimates and issued comparatively weak full-year guidance. This combination of healthy sales momentum and cautious profitability and outlook signals a potential tension between growth initiatives and near-term...

In recent weeks, Laser Photonics Corporation reported that its Laser Shield Anti-Drone system advanced into U.S. Department of War evaluation under the MEIA Vulcan program, while also securing a US$13.20 million follow-on order from the US Navy and a US$250,000 custom medical laser drilling order from Johnson & Johnson. Taken together, these defense and medical wins point to growing third-party validation of Laser Photonics’ laser platforms across mission-critical and high-specification...

Rapport Therapeutics (RAPP) is back in focus after new efficacy data for its lead candidate RAP-219, progress toward Phase 3 planning, and weaker trial results from a competing epilepsy therapy. See our latest analysis for Rapport Therapeutics. Despite the latest data and analyst attention, Rapport Therapeutics’ share price has slipped 8.6% over the past week and 5.1% over the past month. However, its 90 day share price return of 18.2% and one year total shareholder return of about 2x suggest...

KBR, Inc. recently announced that its Mission Technology Solutions business has been awarded a 20-year, US$8.00 billion-ceiling Antarctic Science and Engineering Support Contract by the U.S. National Science Foundation, covering operations, logistics, maintenance, and technical services for all U.S. Antarctic research stations and related field sites. This long-duration, single-award IDIQ contract underscores KBR’s role in complex government science programs and adds a substantial,...

Beam Therapeutics (BEAM) is back in focus after new clinical data for its BEAM-302 program showed sustained protective protein levels. This supports an accelerated FDA review path and helps to reset investor attention on the stock. See our latest analysis for Beam Therapeutics. The fresh BEAM-302 data arrives after a sharp pullback, with a 1-day share price return of down 10.47% and a 7-day share price return of down 10.72%. However, the 1-year total shareholder return of 58.28% contrasts...

In late May 2026, Cheniere Energy Partners, L.P. awarded Bechtel a US$4.69 billion engineering, procurement and construction contract for Train 7 and related infrastructure at its Sabine Pass LNG expansion project in Louisiana. This new contract extends a long-standing collaboration between the two companies at Sabine Pass and signals a substantial multi-decade commitment to expanding US LNG export capacity. We’ll examine how this large Sabine Pass Train 7 contract shapes Cheniere Energy...

Pagaya Technologies recently completed a US$600,000,000 structured notes offering at 100% of principal and reported first-quarter 2026 earnings per share of US$0.73, well ahead of forecasts. Alongside this, CEO Gal Krubiner increased his shareholding and the company appointed Terry O’Neil as Chief Commercial Officer, highlighting management’s commitment to scaling partnerships and products. We’ll now examine how the strong earnings surprise and Terry O’Neil’s appointment as Chief...

Dover recently reported strong first-quarter 2026 results, highlighting solid revenue growth, robust order momentum, and a book-to-bill ratio above one across all five operating segments. Management’s decision to maintain full-year 2026 revenue and adjusted EPS guidance, backed by capacity and productivity investments, underscores growing confidence in the company’s demand outlook. We’ll now examine how Dover’s broad-based order strength and reaffirmed 2026 guidance may influence the earlier...

In recent days, Edgewise Therapeutics announced inducement stock option grants to four new non-executive employees under its 2024 Inducement Equity Incentive Plan, while several Wall Street firms reiterated positive views on the company. Beyond the routine equity awards, the clustering of upbeat analyst opinions highlights how external research coverage can shape investor perception of Edgewise Therapeutics’ longer-term prospects. Next, we’ll examine how this wave of bullish analyst...

In recent months, American International Group (AIG) has experienced leadership changes with CEO Peter Zaffino departing and Eric Anderson taking over, while also reshaping its portfolio by selling its Corebridge Financial stake and acquiring Everest Group Ltd.'s Colombia subsidiary to build out its Latin American insurance footprint. At the same time, AIG’s dividend profile has attracted attention, with a yield above industry and S&P 500 levels and a multi‑year pattern of dividend growth...

In late May 2026, Ropes & Gray and Arkwright Consulting each announced they had selected Intapp’s DealCloud platform, with Ropes & Gray also adopting the new Celeste agentic AI to connect growth, compliance, and profitability workflows. These wins highlight growing real‑world adoption of Intapp’s cloud and AI stack across legal and consulting firms, directly tying its technology roadmap to mission‑critical client workflows. Next, we’ll examine how Celeste’s launch as an agentic AI layer for...